停用英夫利西单抗的克罗恩病患者短期及中远期复发预测血清生物标志物的外部验证
在停用英夫利西单抗的克罗恩病患者中,短期(≤6个月)与中远期(>6个月)复发风险分别与不同的血液蛋白谱相关。本研究在SPARE队列中外部验证该发现,显示前10个生物标志物对在预测短期和中远期复发时的c-statistic均高于CEASE模型、C反应蛋白和粪钙卫蛋白。
要点
- 停用英夫利西单抗后短期复发与高水平的C反应蛋白、触珠蛋白、白细胞介素-6、C型凝集素结构域家族4成员C等相关。
- 中远期复发与低水平的Fms相关酪氨酸激酶3配体、激肽释放酶结合蛋白、成纤维细胞生长因子2等相关。
- 前10个生物标志物对预测短期复发的c-statistic为0.76-0.80,高于CEASE模型0.74、C反应蛋白0.71和粪钙卫蛋白0.69。
核心结论
- 在停用英夫利西单抗的克罗恩病患者中,短期和中远期复发风险与不同的血液蛋白谱相关,具有指导英夫利西单抗撤药的潜力。
研究设计与样本
- 在SPARE队列(前瞻性随机对照试验,比较英夫利西单抗联合抗代谢药、抗代谢药单药和英夫利西单抗单药治疗)中,将持续无激素临床缓解且联合治疗的患者随机分配至继续联合治疗、停用英夫利西单抗或停用免疫抑制剂三组。
- 在STORI和SPARE(停用英夫利西单抗组)队列的基线血清中检测202种免疫相关蛋白。
- 用单变量Cox模型分析与复发时间相关的蛋白,并在STORI与SPARE之间进行比较。
- 通过c-statistic(一致性分析)评估生物标志物(单独及两两组合)的区分能力,并与C反应蛋白、粪钙卫蛋白及既往验证的CEASE模型比较。
主要发现
- 在STORI和SPARE中,不同的血液蛋白谱与短期复发风险相关(例如高水平:C反应蛋白、触珠蛋白、白细胞介素-6、C型凝集素结构域家族4成员C)。
- 在STORI和SPARE中,不同的血液蛋白谱与中远期复发风险相关(例如低水平:Fms相关酪氨酸激酶3配体、激肽释放酶结合蛋白、成纤维细胞生长因子2)。
- 外部验证中,前10个生物标志物对预测短期复发的c-statistic为0.76-0.80,高于CEASE模型的0.74、C反应蛋白的0.71和粪钙卫蛋白的0.69。
- 外部验证中,前10个生物标志物对预测中远期复发的c-statistic为0.66-0.68,高于CEASE模型的0.61、C反应蛋白的0.52和粪钙卫蛋白的0.59。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with Crohn's disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy). DESIGN: In SPARE, patients with CD in sustained steroid-free clinical remission and on combination therapy were randomly allocated to three arms: continuing combination therapy, stopping infliximab or stopping immunosuppressant. In the baseline serum of the STORI and SPARE (arm stopping infliximab) cohorts, we studied 202 immune-related proteins. The proteins associated with time to relapse (univariable Cox model) were compared between STORI and SPARE. The discriminative ability of biomarkers (individually and combined in pairs) was evaluated by the c-statistic (concordance analysis) which was compared with C-reactive protein (CRP), faecal calprotectin and a previously validated model (CEASE). RESULTS: In STORI and SPARE, distinct blood protein profiles were associated with the risk of short-term (eg, high level: CRP, haptoglobin, interleukin-6, C-type lectin domain family 4 member C) and mid/long-term relapse (eg, low level: Fms-related tyrosine kinase 3 ligand, kallistatin, fibroblast growth factor 2). At external validation, the top 10 biomarker pairs showed a higher c-statistic than the CEASE model, CRP and faecal calprotectin in predicting short-term (0.76-0.80 vs 0.74 vs 0.71 vs 0.69, respectively) and mid/long-term relapse (0.66-0.68 vs 0.61 vs 0.52 vs 0.59, respectively). CONCLUSION: In patients with CD stopping infliximab, we confirm that the risk of short-term and mid/long-term relapse is associated with distinct blood protein profiles showing the potential to guide infliximab withdrawal. TRIAL REGISTRATION NUMBER: NCT00571337 and NCT02177071.
引用
- Pierre N, Huynh-Thu VA, Baiwir D, et al. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab. Gut. 2024. PMID: 39134391. doi:10.1136/gutjnl-2024-332648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。